Sarepta Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Sarepta Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA. 

CEO
Douglas S. Ingram
CEODouglas S. Ingram
Employees
1,372
Employees1,372
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1980
Founded1980
Employees
1,372
Employees1,372

SRPT Key Statistics

Market cap
1.88B
Market cap1.88B
Price-Earnings ratio
-6.21
Price-Earnings ratio-6.21
Dividend yield
Dividend yield
Average volume
2.60M
Average volume2.60M
High today
High today
Low today
Low today
Open price
$18.46
Open price$18.46
Volume
0.00
Volume0.00
52 Week high
$111.21
52 Week high$111.21
52 Week low
$10.42
52 Week low$10.42

Stock Snapshot

Sarepta Therapeutics(SRPT) stock is priced at $18.05, giving the company a market capitalization of 1.88B. It carries a P/E multiple of -6.21.

On 2026-02-12, Sarepta Therapeutics(SRPT) stock opened at $18.46, reached a high of —, and a low of —.

Sarepta Therapeutics(SRPT) shares are trading with a volume of 0, against a daily average of 2.6M.

During the past year, Sarepta Therapeutics(SRPT) stock moved between $10.42 at its lowest and $111.21 at its peak.

During the past year, Sarepta Therapeutics(SRPT) stock moved between $10.42 at its lowest and $111.21 at its peak.

SRPT News

Simply Wall St 14h
Has Sarepta Therapeutics Fallen Too Far After Its Sharp Multi‑Year Share Price Slide?

If you are wondering whether Sarepta Therapeutics shares are now pricing in too much pessimism or hiding potential value, this article will walk through what th...

Has Sarepta Therapeutics Fallen Too Far After Its Sharp Multi‑Year Share Price Slide?
The Motley Fool 6d
Arrowhead Q1 2026 Earnings Call Transcript

Image source: The Motley Fool. Thursday, February 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Dr. Christopher Anzalone Chief Operating...

Arrowhead Q1 2026 Earnings Call Transcript
Simply Wall St 7d
Is Sarepta Quietly Redefining Its Rare Disease Strategy With a Huntington’s Trial Bet?

Sarepta Therapeutics, Inc. recently received Medsafe approval in New Zealand for its clinical trial application to begin INSIGHTT, a first-in-human Phase 1 stud...

Is Sarepta Quietly Redefining Its Rare Disease Strategy With a Huntington’s Trial Bet?

Analyst ratings

54%

of 26 ratings
Buy
26.9%
Hold
53.8%
Sell
19.2%

People also own

Based on the portfolios of people who own SRPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.